10 analysts have shared their evaluations of Hologic HOLX during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 3 | 5 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 2 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 1 | 2 | 2 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Hologic, presenting an average target of $86.6, a high estimate of $95.00, and a low estimate of $78.00. Observing a 0.7% increase, the current average has risen from the previous average price target of $86.00.
Investigating Analyst Ratings: An Elaborate Study
The perception of Hologic by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Anthony Petrone | Mizuho | Raises | Outperform | $90.00 | $85.00 |
| Vijay Kumar | Evercore ISI Group | Raises | In-Line | $82.00 | $78.00 |
| Patrick Donnelly | Citigroup | Lowers | Neutral | $85.00 | $95.00 |
| Mike Matson | Needham | Maintains | Buy | $90.00 | $90.00 |
| Conor McNamara | RBC Capital | Maintains | Sector Perform | $82.00 | $82.00 |
| Mason Carrico | Stephens & Co. | Maintains | Overweight | $92.00 | $92.00 |
| Vijay Kumar | Evercore ISI Group | Raises | In-Line | $78.00 | $76.00 |
| Casey Woodring | JP Morgan | Raises | Overweight | $95.00 | $91.00 |
| Conor McNamara | RBC Capital | Raises | Sector Perform | $82.00 | $81.00 |
| Mike Matson | Needham | Maintains | Buy | $90.00 | $90.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Hologic. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Hologic compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Hologic's stock. This comparison reveals trends in analysts' expectations over time.
To gain a panoramic view of Hologic's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Hologic analyst ratings.
Unveiling the Story Behind Hologic
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Hologic: A Financial Overview
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Hologic's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 2.74%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Hologic's net margin excels beyond industry benchmarks, reaching 19.23%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Hologic's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.97% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Hologic's ROA stands out, surpassing industry averages. With an impressive ROA of 2.21%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Hologic's debt-to-equity ratio is below the industry average at 0.52, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Core of Analyst Ratings: What Every Investor Should Know
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
